Maidenhead: Council welcomes biopharmaceutical company Alnylam
US biopharmaceutical company Alnylam opened its UK/Ireland office at Braywick Gate in Maidenhead this week at a special launch attended by council leader councillor Simon Dudley and mayor councillor Sayonara Luxton.
The move has been welcomed by the Royal Borough of Windsor & Maidenhead and follows announcements of the imminent arrival of BlackBerry and Maersk in the town.
Dudley said: “We are delighted to welcome Alnylam to Maidenhead and look forward to a positive relationship with them in the future.
“Maidenhead has an exciting future ahead, with £1 billion of development in the pipeline and Crossrail arriving in 2019.
“The arrival of major companies such as Alnylam, BlackBerry and Maersk show that the potential is recognised and further strengthens the appeal of the town.”
Councillor Jack Rankin, cabinet member for economic development and property, added: “Maidenhead is already home to pharmaceutical companies Glaxosmithkline, Seqirus and Sanofi. Alnylam’s welcome arrival is sure to work to the mutual benefit of the company, which can draw on our skilled workforce, and those seeking employment.”
Brendan Martin, general manager for UK and Ireland at Alnylam, said: ““Maidenhead’s access to highly-skilled individuals and global position in medical sciences will help support Alnylam’s growth in Europe as we pursue clinical development of RNAi therapies in European geographies.
“We look forward to a productive future in the town, with the potential for further expansion in investment in the area, creating more jobs for local people.”
Alnylam’s headquarters are in Cambridge, Massachusetts, USA. It is focused on developing new therapeutics based on RNAi, a biological process of interference with RNA genetic molecules.
